EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieKohortenstudie

Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study

Juliette Logeart, Thomas Samaille, Antoine Falcoz, Magali Svrcek, Olivier Dubreuil, Dewi Vernerey, Romain Cohen, Pascale Cervera, Alain Valverde, Yann Parc, Thierry André

Clinical Colorectal Cancer · 2024

DOI: 10.1016/j.clcc.2024.05.005 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Clinical Colorectal Cancer, 2024. Verfasst von Juliette Logeart und 10 weiteren Autor:innen. Beteiligte Einrichtung: Sorbonne université, Departement of Medical Oncology, Saint Antoine Hospital, APHP, Paris, France; INSERM, Unité Mixte de Recherche Scientifique 938 …. Hauptthemen laut MEDLINE: Colonic Neoplasms, Neoplasm Staging. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Stage II colon cancer (CC) exhibits considerable prognostic heterogeneous. Our objective was to assess survival but also the prognosis impact of microsatellite instability (MSI) in patients with stage IIC (T4bN0M0) CC. PATIENTS AND METHODS: We conducted a retrospective observational study including all patients who had primary stage IIC CC resection between 2010 and 2020 in 2 expert centers. The primary endpoint was overall survival (OS) and disease-free survival (DFS) and time-to-relapse (TTR) were secondary endpoints. RESULTS: Sixty-six patients, median age of 74 years [30-95], were included, with 37.9% presenting MSI (n = 25). Organ invasion involved the last ileal loop (n = 17), another colonic segment (n = 15), omentum (n = 13), visceral peritoneum (n = 13), and the bladder (n = 4). Surgical quality criteria showed complete monobloc resection in all patients and 93.9% R0 resection. After a median follow-up of 5 years [3.5-6.6], the entire population showed a 5-year OS of 65.2% [53.0-80.3] and 5-year DFS of 53.5% [41.1-69.6], with 18.9% [6.8-29.4] experiencing relapses at 5 years. The MSI phenotype correlated with improved 5-year OS (75.5% [56.5-100] vs. 59.5% [44.9-79.0], HR 0.41 [0.17-0.99]; P = .04), but DFS and TTR did not differ. Adjuvant chemotherapy was administered to 34.9% of patients. Univariate analysis identified age > 65 years, MSI status, and the number of nodes as factors associated with OS. CONCLUSION: These data underline, in relation to a low rate of relapse, the lack of consensus regarding the appropriate indication for adjuvant chemotherapy in this high-risk stage II population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsNeoplasm StagingHumansRetrospective StudiesMaleAgedFemaleMiddle AgedAged, 80 and overAdultDisease-Free SurvivalMicrosatellite InstabilityPrognosisNeoplasm Recurrence, LocalColectomySurvival RateChemotherapy, AdjuvantFollow-Up Studies

Stichwörter der Autor:innen

Adjuvant chemotherapyMismatch repair statusPrognosisStage II colon cancerSurgery

Autor:innen und Institutionen

  • Sorbonne université, Departement of Medical Oncology, Saint Antoine Hospital, APHP, Paris, France; INSERM, Unité Mixte de Recherche Scientifique 938 and SIRIC CURAMUS, Centre de Recherche Saint-Antoine, Equipe Instabili…
  • Sorbonne université, Departement of Medical Oncology, Saint Antoine Hospital, APHP, Paris, France.
  • Department of Methodology and Quality of Life Unit in Oncology, University Hospital of Besançon, Besançon, France; University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.
  • Department of Pathology, Saint-Antoine Hospital, AP-HP, Sorbonne Université, Paris, France.
  • Department of Digestive Oncology, Groupe Hospitalier Diaconesses Croix Saint Simon, Paris, France.
  • University Bourgogne Franche-Comté, EFS, INSERM, UMR RIGHT, Besançon, France.

Zitieren

APA

Logeart, J., Samaille, T., Falcoz, A., Svrcek, M., Dubreuil, O., Vernerey, D., Cohen, R., Cervera, P., Valverde, A., Parc, Y., & André, T. (2024). Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study. Clinical Colorectal Cancer. https://doi.org/10.1016/j.clcc.2024.05.005

Vancouver

Logeart J, Samaille T, Falcoz A, Svrcek M, Dubreuil O, Vernerey D, et al. Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study. Clinical Colorectal Cancer. 2024. doi:10.1016/j.clcc.2024.05.005

BibTeX
@article{Logeart2024,
  author = {Logeart, Juliette and Samaille, Thomas and Falcoz, Antoine and Svrcek, Magali and Dubreuil, Olivier and Vernerey, Dewi and Cohen, Romain and Cervera, Pascale and Valverde, Alain and Parc, Yann and André, Thierry},
  title = {Survival Outcomes in Patients with Monobloc-Resected Stage IIC (pT4bN0) Colon Cancer: A Retrospective Observational Cohort Study},
  journal = {Clinical Colorectal Cancer},
  year = {2024},
  doi = {10.1016/j.clcc.2024.05.005}
}
Kostenlos starten →